Loading
Virus Diseases / Gene Editing / Antiviral Therapeutics · Journal article
Journal of Virological Methods · August 12, 2026
Raises a question worth testing. It does not answer one.
This is a narrative review synthesizing emerging applications of CRISPR/Cas systems in antiviral diagnostics and therapeutics, including class 2 effectors (Cas9, Cas12, Cas13) and diagnostic platforms (SHERLOCK, DETECTR, FELUDA). The source identifies potential and challenges—including off-target effects, delivery limitations, and ethical issues—but does not present clinical trial data, efficacy comparisons, or outcome metrics to support practice recommendations.
Narrative review.
Class 2 effectors (Cas9, Cas12, Cas13) target viral DNA and RNA and have potential applications in vaccines against HIV, HPV, HBV, and EBV Diagnostic techniques including SHERLOCK, DETECTR, and FELUDA demonstrate CRISPR's capacity for detecting viral markers Translational challenges identified include off-target effects, delivery limitations, and ethical issues, with proposed mitigation strategies including high-fidelity Cas variants and non-viral delivery systems
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
This is a narrative review surveying emerging CRISPR applications in antiviral therapy and diagnostics, synthesizing concepts and potential rather than reporting original data or clinical evidence.
As stated by the source record.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
What is missing. This record has no reported figures. That is a gap in the analysis, not a judgement about the study.
The CRISPR/Cas (clustered regularly interspaced short palindromic repeats) system is a versatile technology for developing antiviral medicines and editing viral genomes in both diagnostics and vaccine synthesis. Emerging insights into class 2 effectors, such as Cas9, Cas12, and Cas13, which target viral DNA and RNA, have revolutionized vaccines against viruses such as HIV, HPV, HBV, and EBV. Innovative diagnostic techniques such as SHERLOCK, DETECTR, and FELUDA have demonstrated system's diversity and accuracy in detecting the virus markers, supporting clinical decision-making, indicating adaptability and precision of CRISPR. This review critically evaluates CRISPR's role in RNA editing, emphasizing its importance for functional genomics and development of recombinant vaccines. Translational challenges are critically discussed, including off-target effects, delivery limitations, and ethical issues, for which unique approaches such as high-fidelity Cas variants, non-viral delivery systems, and bioethical frameworks are evaluated to address these limitations. This review also covers other social implications, such as accessibility and biosecurity risks, associated with CRISPR technologies Collectively, these advances underscore the transformative potential of CRISPR technologies in shaping next-generation antiviral diagnostics and therapeutics.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.